Extending patent protection through 2035 bolsters MetaVia’s competitive position by restricting generic entry and enhancing licensing opportunities. This intellectual property cushion supports ongoing clinical programs and could increase the company’s long-term valuation as vanoglipel advances toward later-stage trials. MetaVia has compiled a portfolio of 48 granted and pending patents across the U.S., Europe, Japan, China and other jurisdictions, forming three patent families exclusively licensed from Dong-A ST Co. Ltd. These patents secure vanoglipel’s composition, manufacturing methods and formulation rights until at least 2035. The patents encompass the core chemical structure of vanoglipel, its pharmaceutical compositions and potential applications in Metabolic Dysfunction-Associated Steatohepatitis (MASH) and type 2 diabetes. This IP protection underpins vanoglipel’s development as an oral GPR119 agonist, targeting glucose and lipid metabolism and liver inflammation.